BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lisi L, Lacal PM, Barbaccia ML, Graziani G. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. Biochem Pharmacol 2020;180:114169. [PMID: 32710969 DOI: 10.1016/j.bcp.2020.114169] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Burkhardt AM, Lu A, Asante I, Louie S. Pharmacologic Therapeutics for COVID‐19. Coronavirus Disease 2019 (COVID‐19) 2023. [DOI: 10.1002/9781119789741.ch13] [Reference Citation Analysis]
2 Rao N, Poojari T, Poojary C, Sande R, Sawant S. Drug Repurposing: a Shortcut to New Biological Entities. Pharm Chem J 2022. [DOI: 10.1007/s11094-022-02778-w] [Reference Citation Analysis]
3 Robins LI, Keim EK, Robins DB, Edgar JS, Meschke JS, Gafken PR, Williams JF. Modifications of IL-6 by Hypochlorous Acids: Effects on Receptor Binding. ACS Omega 2021;6:35593-9. [PMID: 34984290 DOI: 10.1021/acsomega.1c05297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mukherjee T, Behl T, Sharma S, Sehgal A, Singh S, Sharma N, Mathew B, Kaur J, Kaur R, Das M, Aleya L, Bungau S. Anticipated pharmacological role of Aviptadil on COVID-19. Environ Sci Pollut Res Int 2021. [PMID: 34846667 DOI: 10.1007/s11356-021-17824-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Tammam SN, El Safy S, Ramadan S, Arjune S, Krakor E, Mathur S. Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2. J Control Release 2021;337:258-84. [PMID: 34293319 DOI: 10.1016/j.jconrel.2021.07.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
6 Jovanović JĐ, Antonijević M, El-Emam AA, Marković Z. Comparative MD Study of Inhibitory Activity of Opaganib and Adamantane-Isothiourea Derivatives toward COVID-19 Main Protease Mpro. ChemistrySelect 2021;6:8603-10. [PMID: 34909459 DOI: 10.1002/slct.202101898] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Malykh AG, Pavlov AR, Komkov AV, Volkova YA, Menchikov LG, Zavarzin IV. New synthetic corticosteroids inhibit Epstein–Barr virus release. Mendeleev Communications 2021;31:667-669. [DOI: 10.1016/j.mencom.2021.09.025] [Reference Citation Analysis]
8 Vittaladevaram V, Kuruti K, Urity SV. SARS-COV-2 and COVID-19: A Global Pandemic. Biosci , Biotech Res Asia 2021;18:385-393. [DOI: 10.13005/bbra/2925] [Reference Citation Analysis]
9 Bhatt K, Garimella R, Taugir R, Mehta I, Jamal M, Vijayan R, Offor R, Nwankwo K, Arif U, Waheed K, Kumari P, Lathiya M, Michel G, Pandya N, Halpern J, Nasir H, Sanchez-Gonzalez MA. Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief Review. Infect Chemother 2021;53:1-12. [PMID: 34409778 DOI: 10.3947/ic.2020.0109] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Mahmoudi S, Balmeh N, Mohammadi N, Sadeghian-Rizi T. The Novel Drug Discovery to Combat COVID-19 by Repressing Important Virus Proteins Involved in Pathogenesis Using Medicinal Herbal Compounds. Avicenna J Med Biotechnol 2021;13:107-15. [PMID: 34484639 DOI: 10.18502/ajmb.v13i3.6370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
11 Jicsinszky L, Martina K, Cravotto G. Cyclodextrins in the antiviral therapy. J Drug Deliv Sci Technol 2021;64:102589. [PMID: 34035845 DOI: 10.1016/j.jddst.2021.102589] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
12 Singh N, Villoutreix BO. Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises. Comput Struct Biotechnol J 2021;19:2537-48. [PMID: 33936562 DOI: 10.1016/j.csbj.2021.04.059] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
13 Maxwell D, Sanders KC, Sabot O, Hachem A, Llanos-cuentas A, Olotu A, Gosling R, Cutrell JB, Hsiang MS. COVID-19 therapeutics for low- and middle-income countries: a review of re-purposed candidate agents with potential for near-term use and impact.. [DOI: 10.1101/2021.03.22.21253621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Jena S, Munusami P, Mm B, Chanda K. Computationally approached inhibition potential of Tinospora cordifolia towards COVID-19 targets. Virusdisease 2021;:1-13. [PMID: 33778129 DOI: 10.1007/s13337-021-00666-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
15 Li G, Xu M, Yue T, Gu W, Tan L. Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq. Biochem Pharmacol 2021;185:114485. [PMID: 33617841 DOI: 10.1016/j.bcp.2021.114485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
16 Deb P, Molla MMA, Saif-Ur-Rahman KM. An update to monoclonal antibody as therapeutic option against COVID-19. Biosaf Health 2021;3:87-91. [PMID: 33585808 DOI: 10.1016/j.bsheal.2021.02.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 71] [Article Influence: 32.0] [Reference Citation Analysis]
17 Avanzini MA, Mura M, Percivalle E, Bastaroli F, Croce S, Valsecchi C, Lenta E, Nykjaer G, Cassaniti I, Bagnarino J, Baldanti F, Zecca M, Comoli P, Gnecchi M. Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection. Stem Cells Transl Med 2021;10:636-42. [PMID: 33188579 DOI: 10.1002/sctm.20-0385] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 13.5] [Reference Citation Analysis]
18 Cagno V, Magliocco G, Tapparel C, Daali Y. The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro. Basic Clin Pharmacol Toxicol 2021;128:621-4. [PMID: 33232578 DOI: 10.1111/bcpt.13537] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
19 Arafet K, Serrano-Aparicio N, Lodola A, Mulholland AJ, González FV, Świderek K, Moliner V. Mechanism of inhibition of SARS-CoV-2 Mpro by N3 peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity. Chem Sci 2020;12:1433-44. [PMID: 34163906 DOI: 10.1039/d0sc06195f] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 18.3] [Reference Citation Analysis]